MedPath

A Study of ABT-751 in Patients With Renal Cell Cancer

Phase 2
Completed
Conditions
Renal Cell Cancer
Registration Number
NCT00073112
Lead Sponsor
Abbott
Brief Summary

The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with renal cell cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Objective Response Rate in subjects with RCC1 year
Secondary Outcome Measures
NameTimeMethod
Time to Tumor Progression (TTP)1 year
Survival2 years
Toxicities associated with treatment administration1 year

Trial Locations

Locations (23)

US Oncology Inc Rocky Mountain Cancer Centers

๐Ÿ‡บ๐Ÿ‡ธ

Denver, Colorado, United States

B.C. Vancouver Cancer Agency

๐Ÿ‡จ๐Ÿ‡ฆ

Vancouver, British Columbia, Canada

McGill University

๐Ÿ‡จ๐Ÿ‡ฆ

Montreal, Quebec, Canada

Arizona Cancer Research Center

๐Ÿ‡บ๐Ÿ‡ธ

Tucson, Arizona, United States

McMaster University

๐Ÿ‡จ๐Ÿ‡ฆ

Hamilton, Ontario, Canada

US Oncology Inc Cancer Centers of Florida, P.A.

๐Ÿ‡บ๐Ÿ‡ธ

Orlando, Florida, United States

University of Chicago Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Chicago, Illinois, United States

Sidney Kimmel Comprehensive Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Baltimore, Maryland, United States

US Oncology Inc Raleigh Hematology Oncology Clinic

๐Ÿ‡บ๐Ÿ‡ธ

Cary, North Carolina, United States

UCLA School of Medicine

๐Ÿ‡บ๐Ÿ‡ธ

Los Angeles, California, United States

US Oncology Inc Ocala Oncology Center

๐Ÿ‡บ๐Ÿ‡ธ

Ocala, Florida, United States

Oncology Hematology Group of South Florida

๐Ÿ‡บ๐Ÿ‡ธ

Miami, Florida, United States

Clinical Trials + Research Associates

๐Ÿ‡บ๐Ÿ‡ธ

Montebello, California, United States

US Oncology Inc Florida Cancer Institute

๐Ÿ‡บ๐Ÿ‡ธ

New Port Richey, Florida, United States

US Oncology Inc Cancer Care Accociates-Mercy Campus

๐Ÿ‡บ๐Ÿ‡ธ

Oklahoma City, Oklahoma, United States

US Oncology Inc Dayton Oncology & Hematology P.A.

๐Ÿ‡บ๐Ÿ‡ธ

Kettering, Ohio, United States

US Oncology Inc Cancer Centers of the Carolinas

๐Ÿ‡บ๐Ÿ‡ธ

Greenville, South Carolina, United States

West Cancer Clinic

๐Ÿ‡บ๐Ÿ‡ธ

Memphis, Tennessee, United States

US Oncology Inc Cancer Care Northwest-North

๐Ÿ‡บ๐Ÿ‡ธ

Spokane, Washington, United States

Vanderbilt Ingram Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Nashville, Tennessee, United States

US Oncology Inc Tyler Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Tyler, Texas, United States

US Oncology Inc Northwest Cancer Specialists

๐Ÿ‡บ๐Ÿ‡ธ

Vancouver, Washington, United States

Queen Elizabeth II Health Science Centre

๐Ÿ‡จ๐Ÿ‡ฆ

Halifax, Nova Scotia, Canada

ยฉ Copyright 2025. All Rights Reserved by MedPath